Keytruda And Small Cell Lung Cancer

On june 17 2019 the food and drug administration granted accelerated approval to pembrolizumab keytruda merck for patients with metastatic small cell lung cancer sclc with disease.

Keytruda and small cell lung cancer.

Merck co s keytruda may be the star in non small cell lung cancer but a combo of it and chemo just failed to significantly outdo chemo alone at prolonging patients lives in small cell. The immunotherapy agent keytruda pembrolizumab had an overall response rate orr of 33 percent in a recent trial including patients with extensive stage small cell lung cancer sclc. Findings of the phase 1b keynote 028 trial were published in the journal of clinical oncology. Keytruda is a prescription medicine used to treat a kind of lung cancer called non small cell lung cancer nsclc.

Food and drug administration has accepted merck s application seeking accelerated approval of keytruda pembrolizumab for the treatment of advanced small cell lung cancer sclc patients who failed at least two prior therapies.